MovDisordV3, PascalFrancis, Corpus, bibRecord, 002886

Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [18F]FDG-PET

Identifieur interne : 002886 ( PascalFrancis/Corpus ); précédent : 002885; suivant : 002887

Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [18F]FDG-PET

Auteurs : Georg Berding ; Per Odin ; David J. Brooks ; Guido Nikkhah ; Cordula Matthies ; Thomas Peschel ; Mona Shing ; Hans Kolbe ; Jörg Van Den Hoff ; Harald Fricke ; Reinhard Dengler ; Madjid Samii ; Wolfram H. Knapp

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:02-0177036

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Tomoscintigraphie, Positon, Métabolisme, Glucose, Encéphale, Repos, Exploration, Homme.

English descriptors

KwdEn :
- Brain (vertebrata), Emission tomography, Exploration, Glucose, Human, Metabolism, Parkinson disease, Positron, Rest.

Abstract

Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [¹⁸F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [¹⁸F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [¹⁸F]FDG-PET`
A11	`01`	`1`		`@1 BERDING (Georg)`
A11	`02`	`1`		`@1 ODIN (Per)`
A11	`03`	`1`		`@1 BROOKS (David J.)`
A11	`04`	`1`		`@1 NIKKHAH (Guido)`
A11	`05`	`1`		`@1 MATTHIES (Cordula)`
A11	`06`	`1`		`@1 PESCHEL (Thomas)`
A11	`07`	`1`		`@1 SHING (Mona)`
A11	`08`	`1`		`@1 KOLBE (Hans)`
A11	`09`	`1`		`@1 VAN DEN HOFF (Jörg)`
A11	`10`	`1`		`@1 FRICKE (Harald)`
A11	`11`	`1`		`@1 DENGLER (Reinhard)`
A11	`12`	`1`		`@1 SAMII (Madjid)`
A11	`13`	`1`		`@1 KNAPP (Wolfram H.)`
A14	`01`			`@1 Department of Nuclear Medicine, University Medical School @2 Hannover @3 DEU @Z 1 aut. @Z 9 aut. @Z 10 aut. @Z 13 aut.`
A14	`02`			`@1 Department of Neurology, University of Marburg @2 Marburg @3 DEU @Z 2 aut. @Z 7 aut.`
A14	`03`			`@1 Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital @2 London @3 GBR @Z 3 aut.`
A14	`04`			`@1 Department of Neurosurgery, Nordstadt Hospital and University Medical School @2 Hannover @3 DEU @Z 4 aut. @Z 5 aut. @Z 12 aut.`
A14	`05`			`@1 Department of Neurology, University Medical School @2 Hannover @3 DEU @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 11 aut.`
A20				`@1 1014-1022`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000094252170030`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 53 ref.`
A47	`01`	`1`		`@0 02-0177036`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [¹⁸F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [¹⁸F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Tomoscintigraphie @5 04`
C03	`02`	`X`	`ENG`	`@0 Emission tomography @5 04`
C03	`02`	`X`	`SPA`	`@0 Tomocentelleografía @5 04`
C03	`03`	`X`	`FRE`	`@0 Positon @5 05`
C03	`03`	`X`	`ENG`	`@0 Positron @5 05`
C03	`03`	`X`	`SPA`	`@0 Positrón @5 05`
C03	`04`	`X`	`FRE`	`@0 Métabolisme @5 07`
C03	`04`	`X`	`ENG`	`@0 Metabolism @5 07`
C03	`04`	`X`	`SPA`	`@0 Metabolismo @5 07`
C03	`05`	`X`	`FRE`	`@0 Glucose @2 NK @5 08`
C03	`05`	`X`	`ENG`	`@0 Glucose @2 NK @5 08`
C03	`05`	`X`	`SPA`	`@0 Glucosa @2 NK @5 08`
C03	`06`	`X`	`FRE`	`@0 Encéphale @5 10`
C03	`06`	`X`	`ENG`	`@0 Brain (vertebrata) @5 10`
C03	`06`	`X`	`SPA`	`@0 Encéfalo @5 10`
C03	`07`	`X`	`FRE`	`@0 Repos @5 13`
C03	`07`	`X`	`ENG`	`@0 Rest @5 13`
C03	`07`	`X`	`SPA`	`@0 Descanso @5 13`
C03	`08`	`X`	`FRE`	`@0 Exploration @5 17`
C03	`08`	`X`	`ENG`	`@0 Exploration @5 17`
C03	`08`	`X`	`SPA`	`@0 Exploración @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Exploration radioisotopique @5 45`
C07	`06`	`X`	`ENG`	`@0 Radionuclide study @5 45`
C07	`06`	`X`	`SPA`	`@0 Exploración radioisotópica @5 45`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central @5 61`
C07	`07`	`X`	`ENG`	`@0 Central nervous system @5 61`
C07	`07`	`X`	`SPA`	`@0 Sistema nervioso central @5 61`
N21				`@1 098`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0177036 INIST
ET :	Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [¹⁸F]FDG-PET
AU :	BERDING (Georg); ODIN (Per); BROOKS (David J.); NIKKHAH (Guido); MATTHIES (Cordula); PESCHEL (Thomas); SHING (Mona); KOLBE (Hans); VAN DEN HOFF (Jörg); FRICKE (Harald); DENGLER (Reinhard); SAMII (Madjid); KNAPP (Wolfram H.)
AF :	Department of Nuclear Medicine, University Medical School/Hannover/Allemagne (1 aut., 9 aut., 10 aut., 13 aut.); Department of Neurology, University of Marburg/Marburg/Allemagne (2 aut., 7 aut.); Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital/London/Royaume-Uni (3 aut.); Department of Neurosurgery, Nordstadt Hospital and University Medical School/Hannover/Allemagne (4 aut., 5 aut., 12 aut.); Department of Neurology, University Medical School/Hannover/Allemagne (6 aut., 7 aut., 8 aut., 11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 6; Pp. 1014-1022; Bibl. 53 ref.
LA :	Anglais
EA :	Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [¹⁸F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [¹⁸F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.
CC :	002B17G
FD :	Parkinson maladie; Tomoscintigraphie; Positon; Métabolisme; Glucose; Encéphale; Repos; Exploration; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique; Système nerveux central
ED :	Parkinson disease; Emission tomography; Positron; Metabolism; Glucose; Brain (vertebrata); Rest; Exploration; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study; Central nervous system
SD :	Parkinson enfermedad; Tomocentelleografía; Positrón; Metabolismo; Glucosa; Encéfalo; Descanso; Exploración; Hombre
LO :	INIST-20953.354000094252170030
ID :	02-0177036

Links to Exploration step

Pascal:02-0177036

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [<sup>18</sup>
F]FDG-PET</title>
<author><name sortKey="Berding, Georg" sort="Berding, Georg" uniqKey="Berding G" first="Georg" last="Berding">Georg Berding</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="03"><s1>Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nikkhah, Guido" sort="Nikkhah, Guido" uniqKey="Nikkhah G" first="Guido" last="Nikkhah">Guido Nikkhah</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matthies, Cordula" sort="Matthies, Cordula" uniqKey="Matthies C" first="Cordula" last="Matthies">Cordula Matthies</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peschel, Thomas" sort="Peschel, Thomas" uniqKey="Peschel T" first="Thomas" last="Peschel">Thomas Peschel</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shing, Mona" sort="Shing, Mona" uniqKey="Shing M" first="Mona" last="Shing">Mona Shing</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kolbe, Hans" sort="Kolbe, Hans" uniqKey="Kolbe H" first="Hans" last="Kolbe">Hans Kolbe</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Den Hoff, Jorg" sort="Van Den Hoff, Jorg" uniqKey="Van Den Hoff J" first="Jörg" last="Van Den Hoff">Jörg Van Den Hoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fricke, Harald" sort="Fricke, Harald" uniqKey="Fricke H" first="Harald" last="Fricke">Harald Fricke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dengler, Reinhard" sort="Dengler, Reinhard" uniqKey="Dengler R" first="Reinhard" last="Dengler">Reinhard Dengler</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Samii, Madjid" sort="Samii, Madjid" uniqKey="Samii M" first="Madjid" last="Samii">Madjid Samii</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knapp, Wolfram H" sort="Knapp, Wolfram H" uniqKey="Knapp W" first="Wolfram H." last="Knapp">Wolfram H. Knapp</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0177036</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0177036 INIST</idno>
<idno type="RBID">Pascal:02-0177036</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002886</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [<sup>18</sup>
F]FDG-PET</title>
<author><name sortKey="Berding, Georg" sort="Berding, Georg" uniqKey="Berding G" first="Georg" last="Berding">Georg Berding</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="03"><s1>Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nikkhah, Guido" sort="Nikkhah, Guido" uniqKey="Nikkhah G" first="Guido" last="Nikkhah">Guido Nikkhah</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Matthies, Cordula" sort="Matthies, Cordula" uniqKey="Matthies C" first="Cordula" last="Matthies">Cordula Matthies</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peschel, Thomas" sort="Peschel, Thomas" uniqKey="Peschel T" first="Thomas" last="Peschel">Thomas Peschel</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shing, Mona" sort="Shing, Mona" uniqKey="Shing M" first="Mona" last="Shing">Mona Shing</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kolbe, Hans" sort="Kolbe, Hans" uniqKey="Kolbe H" first="Hans" last="Kolbe">Hans Kolbe</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Den Hoff, Jorg" sort="Van Den Hoff, Jorg" uniqKey="Van Den Hoff J" first="Jörg" last="Van Den Hoff">Jörg Van Den Hoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fricke, Harald" sort="Fricke, Harald" uniqKey="Fricke H" first="Harald" last="Fricke">Harald Fricke</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dengler, Reinhard" sort="Dengler, Reinhard" uniqKey="Dengler R" first="Reinhard" last="Dengler">Reinhard Dengler</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Samii, Madjid" sort="Samii, Madjid" uniqKey="Samii M" first="Madjid" last="Samii">Madjid Samii</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knapp, Wolfram H" sort="Knapp, Wolfram H" uniqKey="Knapp W" first="Wolfram H." last="Knapp">Wolfram H. Knapp</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (vertebrata)</term>
<term>Emission tomography</term>
<term>Exploration</term>
<term>Glucose</term>
<term>Human</term>
<term>Metabolism</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Rest</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Métabolisme</term>
<term>Glucose</term>
<term>Encéphale</term>
<term>Repos</term>
<term>Exploration</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [<sup>18</sup>
F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [<sup>18</sup>
F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [<sup>18</sup>
F]FDG-PET</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BERDING (Georg)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ODIN (Per)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BROOKS (David J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NIKKHAH (Guido)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MATTHIES (Cordula)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PESCHEL (Thomas)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SHING (Mona)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KOLBE (Hans)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>VAN DEN HOFF (Jörg)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>FRICKE (Harald)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>DENGLER (Reinhard)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SAMII (Madjid)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KNAPP (Wolfram H.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Nuclear Medicine, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, University of Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurosurgery, Nordstadt Hospital and University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>1014-1022</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000094252170030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>53 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0177036</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [<sup>18</sup>
F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [<sup>18</sup>
F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Positon</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Positron</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Positrón</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Métabolisme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Metabolism</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Metabolismo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Glucose</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Glucose</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Glucosa</s0>
<s2>NK</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Repos</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Rest</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Descanso</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Exploración</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>61</s5>
</fC07>
<fN21><s1>098</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0177036 INIST</NO>
<ET>Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [<sup>18</sup>
F]FDG-PET</ET>
<AU>BERDING (Georg); ODIN (Per); BROOKS (David J.); NIKKHAH (Guido); MATTHIES (Cordula); PESCHEL (Thomas); SHING (Mona); KOLBE (Hans); VAN DEN HOFF (Jörg); FRICKE (Harald); DENGLER (Reinhard); SAMII (Madjid); KNAPP (Wolfram H.)</AU>
<AF>Department of Nuclear Medicine, University Medical School/Hannover/Allemagne (1 aut., 9 aut., 10 aut., 13 aut.); Department of Neurology, University of Marburg/Marburg/Allemagne (2 aut., 7 aut.); Medical Research Council Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital/London/Royaume-Uni (3 aut.); Department of Neurosurgery, Nordstadt Hospital and University Medical School/Hannover/Allemagne (4 aut., 5 aut., 12 aut.); Department of Neurology, University Medical School/Hannover/Allemagne (6 aut., 7 aut., 8 aut., 11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 6; Pp. 1014-1022; Bibl. 53 ref.</SO>
<LA>Anglais</LA>
<EA>Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 1 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time I hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [<sup>18</sup>
F] acticvity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus, Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [<sup>18</sup>
F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Tomoscintigraphie; Positon; Métabolisme; Glucose; Encéphale; Repos; Exploration; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique; Système nerveux central</FG>
<ED>Parkinson disease; Emission tomography; Positron; Metabolism; Glucose; Brain (vertebrata); Rest; Exploration; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study; Central nervous system</EG>
<SD>Parkinson enfermedad; Tomocentelleografía; Positrón; Metabolismo; Glucosa; Encéfalo; Descanso; Exploración; Hombre</SD>
<LO>INIST-20953.354000094252170030</LO>
<ID>02-0177036</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002886 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002886 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0177036
   |texte=   Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [18F]FDG-PET
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [18F]FDG-PET

Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the Off and On conditions with [18F]FDG-PET

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri